CONMED Corp Issues Preliminary 2026 Financial Guidance at J.P. Morgan Conference
CNMD is trading near its 52-week low of $38.32 (12% above the low).
Summary
CONMED Corporation provided its preliminary financial guidance for the full year 2026, including revenue and adjusted EPS projections, during an investor presentation at the J.P. Morgan Healthcare Conference.
Key Events · Earnings and Guidance · CNMD
-
Preliminary 2026 Revenue Guidance
CONMED Corporation projects full-year 2026 revenue to be between $1,423 million and $1,450 million, representing approximately 4% to 6% constant currency growth.
-
Preliminary 2026 Adjusted EPS Guidance
The company anticipates full-year 2026 adjusted diluted earnings per share to range from $4.25 to $4.45.
-
J.P. Morgan Healthcare Conference Presentation
The guidance was disclosed as part of an investor presentation at the J.P. Morgan Healthcare Conference on January 12, 2026.
Analysis · CNMD · Industrial Applications And Services
The release of preliminary full-year 2026 financial guidance is an important event for investors as it establishes the company's outlook for the upcoming fiscal year. This guidance, presented at a major industry conference, provides key metrics for revenue and adjusted earnings per share, which will be critical for analysts and investors to update their models and expectations for CONMED Corporation's future performance.
At the time of this filing, CNMD was trading at $42.91 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $38.32 to $74.70. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.